Most PDA patients share common pathogenic lesions, including a high frequency of oncogenic KRAS mutations (90–95%) and the inactivation of certain tumour suppressors, such as TP53, P16/INK4A, and SMAD42,3. Here, CDKN2A is linked to Patent ductus arteriosus.